3.9000 0.00 (0.00%)
After hours: 5:09PM EDT
|Bid||3.8900 x 1000|
|Ask||3.9000 x 800|
|Day's Range||3.8400 - 3.9802|
|52 Week Range||2.3200 - 5.1500|
|Beta (3Y Monthly)||1.52|
|PE Ratio (TTM)||86.67|
|Earnings Date||Jun 9, 2017 - Jun 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
Enzo Biochem, Inc. (ENZ) today announced several key transformative initiatives in its labs business unit designed to propel and accelerate growth. The initiatives are part of a company-wide commitment to expand its market opportunity in diagnostic testing, capitalizing on Enzo’s history of innovation, differentiated business strategy and emerging market dynamics.
If you're interested in Enzo Biochem, Inc. (NYSE:ENZ), then you might want to consider its beta (a measure of share...
NEW YORK, NY / ACCESSWIRE / June 11, 2019 / Enzo Biochem, Inc. (NYSE: ENZ ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on June 11, 2019 at 8:30 AM Eastern ...
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday June 25, 2019.
Enzo Biochem, Inc. (ENZ) today announced that on May 7, 2019 it was issued U.S. Patent No. 10,278,960 entitled “Sphingosine Pathway Modulating Compounds for the Treatment of Cancers” that is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the compound Ozanimod. Ozanimod is a product of Celgene Corporation (CELG) that is in late-stage clinical development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease. It targets a different part of the same cell signaling pathway, the “sphingosine pathway,” also targeted by Enzo’s proprietary sphingosine kinase inhibitor, SK1-I, which Enzo is currently developing for the treatment of HCC.
After nearly 38 years, small cap, biotech expert Bill Mathews is retiring as editor of The Cheap Investor; we wish Bill and his wife Karen the very best for their coming years. Meanwhile, we leave our readers with some of Bill's parting comments on some of his favorite biotech ideas.
A look at the shareholders of Enzo Biochem, Inc. (NYSE:ENZ) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the small...
On a per-share basis, the New York-based company said it had a loss of 18 cents. The life sciences and biotechnology company posted revenue of $19.3 million in the period. In the final minutes of trading ...
Enzo Biochem, Inc. , an integrated diagnostics and therapeutics company, today reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services.
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday March 26, 2019.
In 1976 Elazar Rabbani was appointed CEO of Enzo Biochem, Inc. (NYSE:ENZ). First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth thatRead More...
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
The New York-based company said it had a loss of 13 cents per share. The life sciences and biotechnology company posted revenue of $21.3 million in the period. In the final minutes of trading on Monday, ...
Enzo Biochem, Inc. , an integrated diagnostic and therapeutics company, will hold a conference call to discuss fiscal 2019 first quarter results Tuesday, December 11, 2018, at 8:30 AM E.T.
Enzo Biochem, Inc. (ENZ), an integrated diagnostics and therapeutics company, today reported the publication of a study in the Journal of Lipid Research by researchers at a collaborating institution that shows SK1-I, the company’s proprietary Sphingosine Kinase 1 inhibitor drug candidate, was effective in reversing resistance to the breast cancer drug tamoxifen in a tamoxifen-resistant human breast cancer cell line. As pointed out in the publication, endocrine therapy, such as tamoxifen, is a first line treatment for estrogen receptor-positive breast cancer patients.
The big shareholder groups in Enzo Biochem Inc (NYSE:ENZ) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) Endo International PLC (NASDAQ: ENDP ) Krystal Biotech ...